New Jersey 2022-2023 Regular Session

New Jersey Senate Bill S2612

Introduced
5/12/22  

Caption

Requires testing for infectious disease for certain persons who have been administered opioid antidote by first responder.

Impact

The implications of S2612 under the Overdose Prevention Act are significant. It acknowledges the inherent risks that first responders face in their line of duty, particularly in managing potential exposure to infectious diseases during emergency interventions. This legislation balances public health priorities and individual rights by allowing for infectious disease testing, yet it ensures that such testing is only enacted under specific circumstances, thereby respecting the rights of the individuals involved.

Summary

Senate Bill 2612 introduces a critical public health measure aimed at protecting first responders who administer opioid antidotes to individuals experiencing overdoses. The bill mandates that if a first responder has potential exposure to bodily fluids in the process of administering an opioid antidote, they can notify a local public health officer within 24 hours. This notification allows for the possibility of court-ordered testing for infectious diseases such as HIV and hepatitis for the individuals who received the antidote, thereby facilitating important health safeguarding measures for both responders and the public.

Contention

Notable points of contention center around the privacy rights of individuals being tested. The bill stipulates that testing occurs only with consent, or via a court order if consent is not provided within a specified timeframe. This raises ethical questions surrounding the balance between public health interests and personal privacy. Additionally, there are concerns regarding the potential stigma associated with being tested for infectious diseases, along with the ramifications of disclosing such sensitive information within public health contexts. Despite these concerns, supporters argue that the potential risks to first responders warrant a strong public health response.

Companion Bills

NJ A1206

Same As Requires testing for infectious disease for certain persons who have been administered opioid antidote by first responder.

Previously Filed As

NJ A1087

Requires testing for infectious disease for certain persons who have been administered opioid antidote by first responder.

NJ A2648

Requires involuntary commitment of certain individuals who have been administered opioid antidotes.

NJ S4123

Requires involuntary commitment of certain individuals who have been administered opioid antidotes.

NJ H3860

Opioid Overdose Prevention

NJ A160

Requires medical testing for certain persons in circumstances when first responders may be exposed to bloodborne pathogens.

NJ S3904

Prohibits procurement of opioid antidotes from certain entities.

NJ S2031

Requires institutions of higher education to maintain supply of opioid antidotes and permits emergency administration of opioid antidote by campus medical professional or trained employee.

NJ A2124

Requires institutions of higher education to maintain supply of opioid antidotes and permits emergency administration of opioid antidote by campus medical professional or trained employee.

NJ A2278

Clarifies authorization for any person or entity to distribute opioid antidotes.

NJ S2652

Expands entities that may acquire opioid antidotes; creates program within DOH and formalizes reporting requirements.

Similar Bills

No similar bills found.